Effect of Captopril on GLS in Duchenne Myodystrophy

ConditionEffect of Drug

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexMale

Age6+

SponsorAin Shams University

About this trial

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)

Eligibility criteria

Qualifiers

Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS < -18% with minimum age of 6 years old.

Disqualifiers

Any patient who refuses to sign an informed consent.

Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.

Reduced ejection fraction below 50%.

Trial design

Treatments tested in this trial

Captopril Tablets

Treatment groups

20 Participants

are divided into 1 treatment group

Sponsors and collaborators

Ain Shams University

Lead sponsor

Source ClinicalTrials.gov